The post Stellar (XLM) Partner Brale Slashes Stablecoin Launch Costs From $100M appeared on BitcoinEthereumNews.com. Rongchai Wang Jan 22, 2026 15:55 Brale The post Stellar (XLM) Partner Brale Slashes Stablecoin Launch Costs From $100M appeared on BitcoinEthereumNews.com. Rongchai Wang Jan 22, 2026 15:55 Brale

Stellar (XLM) Partner Brale Slashes Stablecoin Launch Costs From $100M



Rongchai Wang
Jan 22, 2026 15:55

Brale CEO Ben Milne explains how the platform eliminates the $100M barrier to stablecoin issuance by bundling licensing, compliance, and blockchain infrastructure.

Launching a regulated stablecoin used to require roughly $100 million and years of groundwork. Brale, a Stellar (XLM)-based infrastructure provider, claims to have collapsed that barrier by packaging banking relationships, state licensing, and blockchain rails into a single platform.

The company’s pitch arrived via a conversation between Stellar Development Foundation CEO Denelle Dixon and Brale founder Ben Milne on the Block by Block podcast. Milne, who previously spent over a decade building USD transfer infrastructure at payments company Dwolla, described Brale as “a big money computer” that handles the unglamorous plumbing most fintech teams can’t afford to build.

Why Stablecoins Cost So Much

The $100 million figure isn’t arbitrary. Traditional stablecoin issuance requires money transmitter licenses across multiple jurisdictions, banking partnerships willing to custody reserves, compliance teams to satisfy regulators, and engineering resources to integrate with blockchain networks. Each piece carries seven-figure costs and multi-year timelines.

Brale centralizes these components. Companies can issue fiat-backed stablecoins on Stellar without assembling their own regulatory and technical stack. The model mirrors what Stripe did for payment processing—abstracting complexity so businesses can focus on their actual product.

Market Timing

The stablecoin sector has grown to $225 billion in dollar-denominated assets, according to recent industry data. That growth has attracted regulatory attention worldwide, with authorities developing frameworks around reserve backing, redemption rights, and anti-money laundering compliance.

Milne believes existing U.S. regulations already accommodate stablecoins adequately—a view not universally shared in Washington. But for companies unwilling to wait for clearer federal guidance, Brale offers a path through state-level licensing.

The approach carries tradeoffs. Centralized infrastructure means trusting Brale’s compliance and custody arrangements. For institutions requiring full control, building in-house remains the only option. But for mid-market players eyeing stablecoin issuance without the capital to match Circle or Tether, the math has changed.

Stellar’s network processed over $8 billion in stablecoin transactions last year, positioning it as a credible alternative to Ethereum for payment-focused use cases. Brale’s infrastructure adds another reason for traditional finance players to consider the chain.

Image source: Shutterstock

Source: https://blockchain.news/news/stellar-brale-stablecoin-issuance-cost-reduction

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26